Skip to main content
Premium Trial:

Request an Annual Quote

Protagen to Use UniArray Platform to Discover Multiple Sclerosis Biomarkers for Biogen Idec


By Justin Petrone

Protagen this week said it will work with Biogen Idec to discover biomarkers related to relapsing or remitting multiple sclerosis.

Under the terms of the agreement, Protagen will use its UniArray protein-chip platform and expertise in autoantibody research to retrospectively analyze samples from a Biogen Idec clinical trial with the goal of identifying predictive and response biomarkers associated with MS therapies.

Protagen is developing its own serum-based assays for the early detection of MS and prostate cancer. It raised $12.7 million last year to fund its test-development program (BAN 9/7/2010).

Protagen CEO Stefan Müllner told BioArray News this week that the company will use its MS signature in the Biogen Idec collaboration. He said the firm's own test is currently undergoing a multicenter, clinical validation. He did not elaborate.

Dortmund, Germany-based Protagen said its UniArray can be used to develop diagnostics based on indication-specific autoantibody patterns in sera and to develop product-specific companion diagnostics and patient-stratification tools for clinical studies.

Protagen has inked a number of biomarker-discovery deals in the past year. In July 2010, it announced a deal with Mikrogen to identify autoantibody signatures in infectious diseases, and in June it expanded a cooperation with Bayer Schering Pharma to discovery biomarkers in endometriosis. Five months later, it partnered with MicroDiscovery to identify and validate biomarkers for undisclosed "medically relevant" diseases.

Müllner said that pharmaceutical companies "recognize more and more the importance of autoantibody signatures for drug development."

Regarding the Biogen Idec agreement, there is an "acute need to discover possible response and non-response biomarkers in MS using genomic and proteomic level markers," Peter Schulz-Knappe, chief scientific officer at Protagen, said in a statement.

He noted that autoantibody signatures "play an increasingly important role as a technology platform that could be used to identify patients for optimized treatment efficacy and to monitor disease progression."

Further details of the deal with Biogen Idec were not discussed.

Have topics you'd like to see covered in BioArray News? Contact the editor at jpetrone [at] genomeweb [.] com.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.